Although these studies provide additional evidence establishing mGluR5 as a potentially effective drug target to antagonize AD progression, additional pharmacological studies will be required in non-human primates to validate the utility of mGluR5 antagonists for the treatment of AD patients. This evidence concerns the gene GRM5 and Alzheimer disease.